Another facet of national opioid epidemic?
Treatment improves progression-free survival versus standard chemotherapy
Scientists demystify popular MS drug
Subcutaneous nanoparticles may help control autoimmune disorders
New study comes amid price-hike furor
Sales staff downplayed drug’s addictive potential, court documents claim
Lantus gets the boot for diabetes
Participants could seek less-costly mix of patients, authors say

P&T September 2016
Table of Contents


Escalating drug prices have seeded interest in value-based purchasing, but confusion and controversy have slowed the Centers for Medicare and Medicaid Services, state agencies, and private insurers from pursuing the potential savings.
As researchers devise ever-more-costly therapies and P&T committees try to balance innovation and affordability, managed care experts warn that the struggle to pay the bills could threaten the sustainability of the nation’s inefficient health care system.
Health Care & Law
Telehealth is becoming mainstream in the U.S., as more consumers, employers, hospital systems, and even insurers adopt the technology. The authors explore the challenges of regulation, reimbursement, and licensing as the modality evolves.
Meeting Highlights
We present sessions on the latest trials and treatments for colorectal cancer from the ESMO World Congress and report on new developments in diagnostics and therapy presented at the European Post-Chicago Melanoma/Skin Cancer Meeting.


Medication Errors
Improve staff training with vendor partnerships
Prescription: Washington
Congress set to tackle biosimilar naming debate
New Drugs/Drug News
Approvals, new indications, regulatory activities, and more
Cabozantinib (Cabometyx) for advanced renal cell carcinoma; glycopyrrolate/formoterol fumarate (Bevespi Aerosphere) for chronic obstructive pulmonary disease; and ephedrine sulfate (Akovaz) for hypotension during anesthesia
Drug Forecast
Aripiprazole lauroxil (Aristada) for the treatment of schizophrenia